Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Minuti

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Annals of Translational Medicine|September 15, 2015
MET deregulation in breast cancerGabriele Minuti, Lorenza Landi
Drugs & Aging|October 9, 2015
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the ElderlyGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Biological Therapy|August 13, 2013
Targeted therapy for NSCLC with driver mutationsGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|April 22, 2014
Protein kinase inhibitors to treat non-small-cell lung cancerGabriele Minuti, Armida D'Incecco, Lorenza Landi, et al.
Current Opinion in Oncology|February 7, 2013
Targeting c-MET in the battle against advanced nonsmall-cell lung cancerLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
MET overexpression and gene amplification in NSCLC: a clinical perspectiveLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
JTO Clinical and Research Reports|December 9, 2025
DESTINY of Immunotherapy in Patients With <i>HER2</i> Mutant Lung Cancer: Case ReportLorenza Landi, Francesca Fusco, Enrico Melis, et al.
Cancer Treatment Reviews|October 23, 2024
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectivesClaudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
JTO Clinical and Research Reports|August 3, 2023
Pretreated <i>EGFR</i><sup></sup>/<i>BRAF</i><sup></sup> Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case ReportCorrado Orciuolo, Federico Cappuzzo, Lorenza Landi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2025
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trialsAndrea Torchia, Arianna Sabatini, Elisabetta Bengala, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Annals of Translational Medicine|September 15, 2015
MET deregulation in breast cancerGabriele Minuti, Lorenza Landi
Drugs & Aging|October 9, 2015
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the ElderlyGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Biological Therapy|August 13, 2013
Targeted therapy for NSCLC with driver mutationsGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|April 22, 2014
Protein kinase inhibitors to treat non-small-cell lung cancerGabriele Minuti, Armida D'Incecco, Lorenza Landi, et al.
Current Opinion in Oncology|February 7, 2013
Targeting c-MET in the battle against advanced nonsmall-cell lung cancerLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
MET overexpression and gene amplification in NSCLC: a clinical perspectiveLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
JTO Clinical and Research Reports|December 9, 2025
DESTINY of Immunotherapy in Patients With <i>HER2</i> Mutant Lung Cancer: Case ReportLorenza Landi, Francesca Fusco, Enrico Melis, et al.
Cancer Treatment Reviews|October 23, 2024
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectivesClaudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
JTO Clinical and Research Reports|August 3, 2023
Pretreated <i>EGFR</i><sup></sup>/<i>BRAF</i><sup></sup> Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case ReportCorrado Orciuolo, Federico Cappuzzo, Lorenza Landi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2025
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trialsAndrea Torchia, Arianna Sabatini, Elisabetta Bengala, et al.
Pageof 5